Hypertension

Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination Compared With Placebo for Initial Treatment of Hypertension

J Am Coll CardiolPublished Randomised controlled trial

Authors' conclusion

In a population with mild-to-moderate BP elevation, both dose versions of the novel low-dose triple single-pill combination showed good tolerability and clinically relevant BP reductions compared with placebo.

Study context

Population
Adults with hypertension receiving 0 to 1 blood pressure (BP)-lowering drugs, home systolic BP (SBP) 130 to 154 mm Hg after 2-week placebo run-in96% completed
Participants
295 adults
Comparison
Low-dose triple single-pill combination vs placebo
Primary endpoint
Difference in change in home SBP from randomization (primary safety: treatment discontinuation due to an adverse event)
Follow-up
Week 4
Methodological detailsinternational, double-blind, placebo-controlled, parallel-group, 2:2:1 randomisation
  • International
  • Double-blind
  • Placebo-controlled
  • Parallel-group
  • 2:2:1 randomisation

Primary result

As reported in the abstract

Home SBP, placebo-corrected least square mean difference

Least square mean difference, mm Hg

GMRx2 ¼ dose
−7.3 (95% CI −4.5 to −10.2)
GMRx2 ½ dose
−8.2 (95% CI −5.2 to −11.3)

Further findings

Clinic BP control (<140/90 mm Hg) · Week 4

  • Clinic BP control (<140/90 mm Hg): both doses P < 0.001 vs placebo

Clinic BP reduction (placebo-corrected) · Week 4

GMRx2 ¼ dose
8.0/4.0 mm Hg
GMRx2 ½ dose
9.5/4.9 mm Hg

Safety

Out of normal range serum sodium or potassium

OutcomeGMRx2 ¼ doseeventsGMRx2 ½ dosePlacebo
Treatment discontinuation due to an adverse event (primary safety outcome)05.1%1.6%
Serious adverse events02 events2 events
  • Out of normal range serum sodium or potassium: no participant had a serum sodium <130/>150 mmol/L or potassium <3.0/>6.0 mmol/L

Original publication

Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination Compared With Placebo for Initial Treatment of Hypertension. J Am Coll Cardiol. Published 31 August 2024. doi:10.1016/j.jacc.2024.08.025

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.